The ad hoc prescription of H1‐antihistamines for mild and/or nonspecific allergy symptom management in infrequent users might account for the trend of decreased mortality risk by reversing malignancy‐specific immune evasion and ICI resistance via the histamine–HRH1 axis. The gene discussed is HRH1; the disease is Allergy.